Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sonoki, T.
Right arrow Articles by Dyer, M. J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sonoki, T.
Right arrow Articles by Dyer, M. J. S.
Related Collections
Right arrow Neoplasia
Right arrow Cell Cycle
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 1 November 2001, Vol. 98, No. 9, pp. 2837-2844

NEOPLASIA

Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies

Takashi Sonoki, Lana Harder, Doug E. Horsman, Loraine Karran, Izumi Taniguchi, Tony G. Willis, Stefan Gesk, Doris Steinemann, Emanuele Zucca, Brigitte Schlegelberger, Francesc Solé, Andrew J. Mungall, Randy D. Gascoyne, Reiner Siebert, and Martin J. S. Dyer

From the Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, Sutton, United Kingdom; Institute of Human Genetics, University Hospital, Kiel, Germany; Department of Pathology, British Columbia Cancer Agency, Vancouver, Canada; Internal Medicine II, Kumamoto University School of Medicine, Kumamoto, Japan; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Laboratory of Cytogenetics and Molecular Genetics, Department of Pathology, Hospital del Mar IMAs IMIM, Barcelona, Spain; and The Sanger Centre, Wellcome Trust Genome Campus, Cambridge, United Kingdom.

Chromosomal translocation t(6;14)(p21.1;q32.3) has been reported as a rare but recurrent event not only in myeloma and plasma cell leukemia but also in diffuse large B-cell non-Hodgkin lymphoma (B-NHL) (diffuse large B-cell lymphoma [DLBCL]) and splenic lymphoma with villous lymphocytes (SLVL); however, the nature of the target gene(s) has not been determined. This study identified t(6;14)(p21.1;q32.3) in 3 cases of transformed extranodal marginal zone B-NHL, in 1 case of SLVL, and in 1 case of a low-grade B-cell lymphoproliferative disorder. In a sixth case, a CD5+ DLBCL, the translocation was identified by molecular cloning in the absence of cytogenetically detectable change. Two chromosomal translocation breakpoints were cloned by using long-distance inverse polymerase chain reaction methods. Comparison with the genomic sequence for chromosome 6p21.1 showed breakpoints approximately 59 and 73.5 kilobases 5' of the cyclin D3 (CCND3) gene with no other identifiable transcribed sequences in the intervening region. Although Southern blotting with derived genomic 6p21.1 probes failed to detect other rearrangements, fluorescent in situ hybridization assays, using BAC (bacterial artificial chromosome) clones spanning and flanking the CCND3 locus, along with probes for IGH confirmed localization of 6p21.1 breakpoints within the same region, as well as fusion of the CCND3 and IGH loci. Furthermore, in all cases, high-level expression of CCND3 was demonstrated at RNA and/or protein levels by Northern and Western blotting and by immunohistochemistry. These data implicate CCND3 as a dominant oncogene in the pathogenesis and transformation in several histologic subtypes of mature B-cell malignancies with t(6;14)(p21.1;q32.3) and suggest that CCND3 overexpression seen in about 10% of DLBCL cases may have a genetic basis.

© 2001 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
haematolHome page
A. Mozos, C. Royo, E. Hartmann, D. De Jong, C. Baro, A. Valera, K. Fu, D. D. Weisenburger, J. Delabie, S.-S. Chuang, et al.
SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype
Haematologica, November 1, 2009; 94(11): 1555 - 1562.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
I. Nagel, T. Akasaka, W. Klapper, S. Gesk, S. Bottcher, M. Ritgen, L. Harder, M. Kneba, M. J.S. Dyer, and R. Siebert
Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma
Haematologica, July 1, 2009; 94(7): 1020 - 1023.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
I. Wlodarska, D. Dierickx, V. Vanhentenrijk, K. Van Roosbroeck, H. Pospisilova, F. Minnei, G. Verhoef, J. Thomas, P. Vandenberghe, and C. De Wolf-Peeters
Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas
Blood, June 15, 2008; 111(12): 5683 - 5690.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Nakamura, H. Ye, C. M. Bacon, A. Goatly, H. Liu, L. Kerr, A. H. Banham, B. Streubel, T. Yao, M. Tsuneyoshi, et al.
Translocations Involving the Immunoglobulin Heavy Chain Gene Locus Predict Better Survival in Gastric Diffuse Large B-Cell Lymphoma
Clin. Cancer Res., May 15, 2008; 14(10): 3002 - 3010.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Fu, D. D. Weisenburger, T. C. Greiner, S. Dave, G. Wright, A. Rosenwald, M. Chiorazzi, J. Iqbal, S. Gesk, R. Siebert, et al.
Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling
Blood, December 15, 2005; 106(13): 4315 - 4321.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. F. Peterson, A. Boyapati, V. Ranganathan, A. Iwama, D. G. Tenen, S. Tsai, and D.-E. Zhang
The Hematopoietic Transcription Factor AML1 (RUNX1) Is Negatively Regulated by the Cell Cycle Protein Cyclin D3
Mol. Cell. Biol., December 1, 2005; 25(23): 10205 - 10219.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Kasugai, H. Tagawa, Y. Kameoka, Y. Morishima, S. Nakamura, and M. Seto
Identification of CCND3 and BYSL as Candidate Targets for the 6p21 Amplification in Diffuse Large B-Cell Lymphoma
Clin. Cancer Res., December 1, 2005; 11(23): 8265 - 8272.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Pruneri, L. Pignataro, S. Valentini, S. Fabris, P. Maisonneuve, N. Carboni, S. Pece, M. Capra, B. Del Curto, A. Neri, et al.
Cyclin D3 Immunoreactivity Is an Independent Predictor of Survival in Laryngeal Squamous Cell Carcinoma
Clin. Cancer Res., January 1, 2005; 11(1): 242 - 248.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
G. Troen, V. Nygaard, T.-K. Jenssen, I. M. Ikonomou, A. Tierens, E. Matutes, A. Gruszka-Westwood, D. Catovsky, O. Myklebost, G. Lauritzsen, et al.
Constitutive Expression of the AP-1 Transcription Factors c-jun, junD, junB, and c-fos and the Marginal Zone B-Cell Transcription Factor Notch2 in Splenic Marginal Zone Lymphoma
J. Mol. Diagn., November 1, 2004; 6(4): 297 - 307.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S. Song, J. Cooperman, D. L. Letting, G. A. Blobel, and J. K. Choi
Identification of Cyclin D3 as a Direct Target of E2A Using DamID
Mol. Cell. Biol., October 1, 2004; 24(19): 8790 - 8802.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Sanchez-Izquierdo, G. Buchonnet, R. Siebert, R. D. Gascoyne, J. Climent, L. Karran, M. Marin, D. Blesa, D. Horsman, A. Rosenwald, et al.
MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma
Blood, June 1, 2003; 101(11): 4539 - 4546.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. A. Martinez-Climent, A. A. Alizadeh, R. Segraves, D. Blesa, F. Rubio-Moscardo, D. G. Albertson, J. Garcia-Conde, M. J. S. Dyer, R. Levy, D. Pinkel, et al.
Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations
Blood, April 15, 2003; 101(8): 3109 - 3117.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Zhang, C.-Y. Yu, and B. Singer
Cell and tumor classification using gene expression data: Construction of forests
PNAS, April 1, 2003; 100(7): 4168 - 4172.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. Franco, A. M. Florena, and E. Iannitto
Splenic marginal zone lymphoma
Blood, April 1, 2003; 101(7): 2464 - 2472.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Sanchez-Beato, A. Sanchez-Aguilera, and M. A. Piris
Cell cycle deregulation in B-cell lymphomas
Blood, February 15, 2003; 101(4): 1220 - 1235.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Satterwhite, T. Sonoki, T. G. Willis, L. Harder, R. Nowak, E. L. Arriola, H. Liu, H. P. Price, S. Gesk, D. Steinemann, et al.
The BCL11 gene family: involvement of BCL11A in lymphoid malignancies
Blood, December 1, 2001; 98(12): 3413 - 3420.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020